Scarica l'app Stockscreener
17.60
3.41%
0.58
Dopo l'orario di chiusura:
17.32
-0.28
-1.59%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CSTL Giù?
Forum
Previsione
Castle Biosciences Inc Borsa (CSTL) Ultime notizie
Two Sigma Advisers LP Acquires New Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Squarepoint Ops LLC Lowers Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards® - The Manila Times
Castle Biosciences’ Founder, President and CEO Derek - GlobeNewswire
ProShare Advisors LLC Makes New $230,000 Investment in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences, Inc. (CSTL) Unveils Largest Real-World Melanoma Risk Study at ASCO 2025 - Insider Monkey
Castle Biosciences Presents Innovative Research on Melanoma Risk Stratification at ASCO 2025 - Nasdaq
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's - GlobeNewswire
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to - GuruFocus
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Rating of “Buy” by Brokerages - Defense World
Man Group plc Buys Shares of 13,302 Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Nuveen Asset Management LLC Has $12.41 Million Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Deutsche Bank AG Buys 7,495 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Bank of America Corp DE Raises Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences amends charter, stockholders vote By Investing.com - Investing.com India
Castle Biosciences Holds Annual Stockholders Meeting - TipRanks
Castle Biosciences amends charter, stockholders vote - Investing.com
Some Confidence Is Lacking In Castle Biosciences, Inc. (NASDAQ:CSTL) As Shares Slide 28% - simplywall.st
Castle Biosciences stock hits 52-week low at $15.66 By Investing.com - Investing.com Australia
Scotiabank Issues Pessimistic Forecast for Castle Biosciences (NASDAQ:CSTL) Stock Price - Defense World
Castle Biosciences (CSTL) Target Price Updated by Scotiabank | C - GuruFocus
Castle Biosciences (CSTL) Target Price Updated by Scotiabank | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Price Target Revised by Scotiabank | C - GuruFocus
Castle Biosciences to Present at the 2025 Jefferies Global Healt - GuruFocus
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference | CSTL Stock News - GuruFocus
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Castle Biosciences Executive Team Reveals Strategic Updates at Jefferies Healthcare Conference - Stock Titan
90,563 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Purchased by D. E. Shaw & Co. Inc. - Defense World
Ameriprise Financial Inc. Has $8.42 Million Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Northern Trust Corp Boosts Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Jane Street Group LLC Reduces Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Voya Investment Management LLC Sells 668 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Price T Rowe Associates Inc. MD Purchases 1,837 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences confirms UM test’s efficacy - Investing.com
Castle Biosciences confirms UM test’s efficacy By Investing.com - Investing.com India
Castle Biosciences (CSTL) Presents New Data on Uveal Melanoma Ri - GuruFocus
Castle Biosciences to buy Previse - MSN
Castle Biosciences (CSTL) Presents New Data on Uveal Melanoma Risk Prediction | CSTL Stock News - GuruFocus
Castle Biosciences Reports Independent Validation of DecisionDx-UM Test with PRAME Gene Expression Data at ARVO 2025 - Nasdaq
Real-World Study Confirms Long-Term Performance of - GlobeNewswire
Texas public company to acquire Baltimore cancer diagnostic firm - The Business Journals
Castle Biosciences projects $287-$297M revenue for 2025 amid strategic acquisitions and growth initiatives - MSN
Canaccord Genuity Group Has Lowered Expectations for Castle Biosciences (NASDAQ:CSTL) Stock Price - Defense World
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2025 Earnings Call Transcript - Insider Monkey
Castle Biosciences (CSTL) Champions Skin Cancer Awareness Initiatives | CSTL Stock News - GuruFocus
Castle Biosciences Celebrates Skin Cancer Awareness Month - The Manila Times
Castle Biosciences Partners with Melanoma Organizations to Promote Skin Cancer Awareness and Education in May - Nasdaq
Castle Biosciences (CSTL) Rating Maintained as Price Target Lowe - GuruFocus
Castle Biosciences (CSTL) Rating Maintained as Price Target Lowered | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Reports Strong Q1 2025 Revenue Growth - GuruFocus
Castle Biosciences (CSTL) Target Price Reduced Despite Strong Re - GuruFocus
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Castle Biosciences (CSTL) Target Price Reduced Despite Strong Revenue Report | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Receives Price Target Adjustment by Ca - GuruFocus
0.40%
1.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):